The Promise of MPTs
Bethany Young Holt, PhD MPH
NICHD Contraceptive Development Meeting
Baylor School of Medicine
November 3-6, 2019
Women’s Sexual & Reproductive Health Risks Are Interlinked

- Unintended Pregnancy
- HIV
- Other Sexually Transmitted Infections (STIs)

Women need better protection
89 million unintended pregnancies occur annually worldwide.

830 women die every day from pregnancy and childbirth-related complications in developing countries.
HIV is the leading killer of women aged 15–44 and the leading cause of death for women of reproductive age.

Worldwide, 1 million STIs are contracted every day.

Infertility—much of it related to treatable STIs—is estimated to affect 186 million couples worldwide.
Multipurpose Prevention Technologies

MPTs combine protection against:

• Unintended pregnancy
• HIV
• Other STIs

MPTs have the potential to:

• Address overlapping risks
• Increase motivation for adherence
• Destigmatize HIV prevention
• Improve health & economic outcomes
More Choices…

- Vaginal inserts and films
- Antibody-based products
- Microarray patches
- IUDs and implant technologies
- On-demand gels
- New condom designs
- New vaginal ring designs
- Co-formulated & co-encapsulated oral contraceptive MPTs
Contraceptive MPTs in Development

### Preclinical
- 3D Printed IVR [HIV, HSV-2]
- BioRings™ IVR [HIV]*
- Elvitegravir + Copper IUS [HIV]*
- Etonogestrel + Ethinyl Estradiol + Qgriffithsin IVR [HIV, HPV, HSV-2]
- HCA + VRC01+ N6 IVR [HIV]*
- HER 102 [Gonorrhea]*
- MPT Microarray Patch [HIV]
- OB-001 Gel [HIV]*
- SAMMA Gel [Chlamydia, Gonorrhea, HIV, HPV, HSV-2]*
- SCHIELD Implant [HIV]
- TDF + FTC + ACV + Ethinyl Estradiol + Etonogestrel IVR [HIV, HSV-2]

### Clinical
- Amphora Gel – Phase 3 [Chlamydia, Gonorrhea]*
- Dapivirine + Levonorgestrel IVR – Phase 1 [HIV]
- MB66+ - Phase 0 [HIV, HSV-2]*
- MIZC Gel + SILCS – Phase 2 [HIV, HPV, HSV-2]*
- Tenofovir + Levonorgestrel IVR – Phase 1 [HIV, HSV-2]

### Fast Tracked
- Co-formulated oral contraceptive MPT [HIV]
- Over-encapsulated oral contraceptive MPT [HIV]

[Additional indications beyond contraception], * Non-hormonal contraceptives
A global market exists for MPTs

- Contraceptive market—$20 billion
- Market for condoms alone—$8 billion
- HIV care, treatment & prevention—$48.9 billion
- Global STI treatment market—$35 billion growing to $84 billion by 2026
IMPT Learning Network

LEARNING NETWORKS ARE COLLABORATIONS THAT WORK TO SOLVE COMPLEX PROBLEMS and achieve a shared vision by enabling groups of stakeholders to cultivate connections, share information, and learn from one another. The IMPT is an international, interdisciplinary learning network united by an agenda to improve the comprehensive sexual and reproductive health of women and girls worldwide by advancing the development of multipurpose prevention technologies (MPTs).

INFORMATION OUT: serves as an information hub, both actively through convenings and live webinars and more passively through an online resource center

INFORMATION IN: constantly gathers and synthesizes field-relevant data from network members

INFORMATION ACROSS: helps stakeholders connect with each other directly in order to foster self-organization, support members to coordinate the activities they’re working on, and avoid duplication of efforts

Critical Technical & End-User Gaps

- Combining active pharmaceutical ingredients
- Pharmacokinetics and drug-drug interactions
- Hormonal contraception (HC) and antiretrovirals
- New non-HC and anti-infective prevention APIs
- Preferred product preferences in target populations
- Commercialization potential
- Pre-clinical and clinical strategies
- Future clinical trial mechanisms
Identification of MPT Fieldwide Priorities and Gaps:

Strategic Actions for Hormonal Contraceptives + Antiretrovirals

- Landscape assessment of male and female non-hormonal contraceptives
- Key informant interviews with experts
- Identification of key themes and potential action areas
- Vetting of action areas with experts at this meeting!
- Peer reviewed publication

Strategic Actions for Non-Hormonal Contraceptives + Anti-infectives

- Status to date:
  - Landscape assessment of male and female non-hormonal contraceptives
  - Key informant interviews with experts
  - Identification of key themes and potential action areas

A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV

Bethany Young Holt, Laura Delplin, Mitchell D. Creinin, Kevin J. Peina, Joseph Romano & Anike Hemmerling

To cite this article: Bethany Young Holt, Laura Delplin, Mitchell D. Creinin, Kevin J. Peina, Joseph Romano & Anike Hemmerling (2018) A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. The European Journal of Contraception & Reproductive Health Care, 23:5, 330-334, DOI: 10.1080/13625187.2018.1505952

To link to this article: https://doi.org/10.1080/13625187.2018.1505952
Innovation can’t wait
MPTs have the potential to usher in a contraceptive revolution by bridging issues that benefit society, invigorate economies, and improve the health of women, families, and our planet.
Connect with the IMPT to learn more about MPT products in the pipeline and opportunities to advance solutions for women’s sexual and reproductive health.

www.theimpt.org
Thank You!

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the Initiative for MPTs (IMPT), CAMI Health, the Public Health Institute (PHI), and its partners and do not necessarily reflect the views of USAID or the U.S. Government. The IMPT is a project of CAMI Health, an organization dedicated to women’s reproductive health and empowerment, housed at PHI.